Precigen Inc (OQ:PGEN)

Sector:  Healthcare Industry:  Pharmaceuticals
 
See Regulatory Filings on SEC
Company Contact
Address: 20374 SENECA MEADOWS PARKWAY
GERMANTOWN MD 20876
Tel: N/A
Website: https://precigen.com
IR: See website
<
Key People
Randal Joe Kirk
Executive Chairman of the Board
Helen Sabzevari
President, Chief Executive Officer, Director; President of PGEN Therapeutics, Inc.
Harry Thomasian
Chief Financial Officer
Rutul R. Shah
Chief Operating Officer
Jeffrey T. Perez
Senior Vice President - Intellectual Property Affairs
Donald P. Lehr
Chief Legal Officer, Corporate Secretary
Business Overview
Precigen, Inc. is a dedicated discovery and clinical-stage biopharmaceutical company advancing gene and cell therapies. The Company's proprietary technology platforms develops product candidates designed to target urgent and intractable diseases in its core therapeutic areas of immuno-oncology, autoimmune disorders and infectious diseases. It has developed a pipeline of therapies across multiple indications. The Company operates through two segments: Biopharmaceuticals and Exemplar. Biopharmaceuticals segment is primarily comprised of the Company's legal entities of Precigen and ActoBio, as well as royalty interests in therapeutics and therapeutic platforms from companies not controlled by the Company. Exemplar segment is composed of Exemplar Genetics LLC, doing business as Precigen Exemplar (Exemplar), its wholly owned subsidiary focused on developing research models and services for healthcare research applications.
Financial Overview
For the fiscal year ended 31 December 2023, Precigen Inc revenues decreased 77% to $6.2M. Net loss before extraordinary items increased 20% to $95.9M. Revenues reflect Biopharmaceuticals segment decrease of 99% to $75K, Exemplar segment decrease of 49% to $6.2M. Higher net loss reflects Impairment of goodwill increase from $482K to $10.4M (expense), Research & Development - Balancing value increase of 3% to $46.4M (expense).
Employees: 202 as of Dec 31, 2023
Reporting Currency: U.S. Dollars
Enterprise value: $298.08M as of Dec 31, 2023
Annual revenue (TTM): $6.23M as of Dec 31, 2023
EBITDA (TTM): -$82.26M as of Dec 31, 2023
Net annual income (TTM): -$95.90M as of Dec 31, 2023
Free cash flow (TTM): -$68.47M as of Dec 31, 2023
Net Debt Last Fiscal Year: N/A
Shares outstanding: 248,919,096 as of Feb 15, 2024
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.